Comparative Activity of Telithromycin Against Macrolide-Resistant Isolates of Streptococcus pneumoniae: Results of Two Years of the PROTEKT Surveillance Study

Abstract The increase in resistance to macrolides has been linked with increasing use of these agents as empirical therapy for community-acquired respiratory tract infections (CARTIs). As part of the ongoing PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) surveillance program, over 7600 Streptococcus pneumoniae isolates were collected worldwide from 1999-2001 and evaluated for macrolide resistance. Globally, macrolide resistance was 31-33%, with considerable inter-country variation (<10-88%) and particularly high prevalence in the Far East (>71%). In Europe, France had the most resistant isolates (>53%). The highest rates of macrolide resistance were seen in 0-2 year olds. Co-resistance to clindamycin (64%) and all b-lactams (14-79%) was seen among macrolide-resistant isolates, but >99% of these isolates were susceptible to telithromycin, vancomycin and linezolid. There was considerable variation in the prevalence of erm(B) (56-64%) and mef(A) (30-35%): erm(B) was prevalent in Europe and mef(A) in North America. Globally, 5-7% isolates carried both mechanisms (erm(B)+mef(A)); of these, 47-65% were from South Korea. These double resistance isolates were >90% resistant to the b-lactams, except amoxicillin-clavulanate. Clindamycin was active against >98% mef(A) but poorly active against erm(B) and erm(B)+mef(A) isolates. Telithromycin, vancomycin and linezolid were highly active (>99.5%) across all three genotypes. Conclusions: In vitro, telithromycin, vancomycin and linezolid are highly active against antibiotic-resistant strains of S. pneumoniae. Telithromycin may be a useful therapeutic alternative to macrolides for the treatment of CARTIs.

[1]  J. Poehlsgaard,et al.  Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study , 2003, Antimicrobial Agents and Chemotherapy.

[2]  I. Morrissey,et al.  Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. , 2002, The Journal of antimicrobial chemotherapy.

[3]  D. Felmingham.  The need for antimicrobial resistance surveillance. , 2002, The Journal of antimicrobial chemotherapy.

[4]  F. Martinez,et al.  Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Leclercq,et al.  Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae , 2002, Antimicrobial Agents and Chemotherapy.

[6]  J. Verhaegen,et al.  IN VITRO ACTIVITY OF THE NEW KETOLIDE TELITHROMYCIN AND OTHER ANTIBIOTICS AGAINST STREPTOCOCCUS PNEUMONIAE IN BELGIUM. , 2001, Acta clinica Belgica.

[7]  I. Morrissey,et al.  Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. , 2001, The Journal of antimicrobial chemotherapy.

[8]  T. Klaukka,et al.  Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  G. Doern,et al.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. W. Yung,et al.  Macrolide Resistance in Streptococcus pneumoniae in Hong Kong , 2001, Antimicrobial Agents and Chemotherapy.

[11]  K. Seme,et al.  The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. , 2001, The Journal of antimicrobial chemotherapy.

[12]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[13]  P. Courvalin,et al.  Two New Mechanisms of Macrolide Resistance in Clinical Strains ofStreptococcus pneumoniae from Eastern Europe and North America , 2000, Antimicrobial Agents and Chemotherapy.

[14]  A. Marchese,et al.  Resistance patterns of lower respiratory tract pathogens in Europe. , 2000, International journal of antimicrobial agents.

[15]  A. Schuchat,et al.  The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. , 2000, The Journal of infectious diseases.

[16]  M. Jacobs,et al.  Mutations in 23S rRNA and Ribosomal Protein L4 Account for Resistance in Pneumococcal Strains Selected In Vitro by Macrolide Passage , 2000, Antimicrobial Agents and Chemotherapy.

[17]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.

[19]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. , 1999, The Journal of antimicrobial chemotherapy.

[20]  G. Doern,et al.  Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Marchese,et al.  Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy. , 1999, The Journal of antimicrobial chemotherapy.

[22]  C. Pai,et al.  Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. H. Hansen,et al.  The macrolide–ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA , 1999, Molecular microbiology.

[24]  Steven D. Brown,et al.  In Vitro Activities of the Ketolide HMR 3647 against Recent Gram-Positive Clinical Isolates and Haemophilus influenzae , 1998, Antimicrobial Agents and Chemotherapy.

[25]  A. Didier,et al.  Guidelines for management of adult community-acquired lower respiratory tract infections , 1998 .

[26]  R. Marre,et al.  Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of , 1998, The Journal of antimicrobial chemotherapy.

[27]  A. Girard,et al.  Ketolides lack inducibility properties of MLS(B) resistance phenotype. , 1997, The Journal of antimicrobial chemotherapy.

[28]  J. Sutcliffe,et al.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system , 1996, Antimicrobial agents and chemotherapy.

[29]  R N Grüneberg,et al.  Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. , 1996, Diagnostic microbiology and infectious disease.

[30]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[31]  R. Leclercq,et al.  Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification , 1991, Antimicrobial Agents and Chemotherapy.

[32]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[33]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[34]  S. Pyo,et al.  High incidence of multidrug-resistant Streptococcus pneumoniae in South Korea. , 1996, Microbial drug resistance.

[35]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[36]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .